Gadolinium
- Generic Name
- Gadolinium
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- Gd
- CAS Number
- 7440-54-2
- Unique Ingredient Identifier
- AU0V1LM3JT
- Background
Gadolinium is under investigation in Hypertension, ACUTE KIDNEY INJURY, and Chronic Kidney Disease. Gadolinium has been investigated for the basic science of CAD, Multiple Sclerosis, and Coronary Artery Disease.
- Associated Conditions
- -
- Associated Therapies
- -
Reducing the Incidence of Symptomatic Brain Metastases With MRI Surveillance
- Conditions
- Interventions
- First Posted Date
- 2023-01-20
- Last Posted Date
- 2024-06-14
- Lead Sponsor
- Wake Forest University Health Sciences
- Target Recruit Count
- 60
- Registration Number
- NCT05692635
- Locations
- 🇺🇸
Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, North Carolina, United States
18F-DCFPyL PET/MRI in Regional Nodal&Distant Metastases Detection in Intermediate &HR Prostate Cancer
- Conditions
- First Posted Date
- 2021-03-22
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Stanford University
- Registration Number
- NCT04809584
- Locations
- 🇺🇸
Stanford University, Stanford, California, United States
CytoreductiveSurgery & HIPEC w/Gemcitabine+Chemotherapy w/Dacarbazine in Uterine Leiomyosarcoma
- Conditions
- Interventions
- First Posted Date
- 2021-01-27
- Last Posted Date
- 2024-03-05
- Lead Sponsor
- Kristen Ganjoo
- Target Recruit Count
- 25
- Registration Number
- NCT04727242
- Locations
- 🇺🇸
Stanford University, Stanford, California, United States
Study of Tumor Treating Fields With Hypofractionated Chemoradiotherapy in Newly Diagnosed Glioblastoma
- Conditions
- Interventions
- First Posted Date
- 2020-07-16
- Last Posted Date
- 2024-06-21
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 12
- Registration Number
- NCT04474353
- Locations
- 🇺🇸
Stanford University, Stanford, California, United States
Gadolinium and Ferumoxytol MRI in Diagnosing Patients With Abnormalities in the Central Nervous System
- First Posted Date
- 2017-09-01
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 150
- Registration Number
- NCT03270059
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
Chronic Convection Enhanced Delivery of Topotecan
- Conditions
- Interventions
- First Posted Date
- 2017-05-16
- Last Posted Date
- 2022-07-05
- Lead Sponsor
- Jeffrey N. Bruce
- Target Recruit Count
- 5
- Registration Number
- NCT03154996
- Locations
- 🇺🇸
Columbia University Irving Medical Center, New York, New York, United States
Metabolic Characteristics of Brain Tumors Using Hyperpolarized Carbon-13 Magnetic Resonance Spectroscopic Imaging (MRSI)
- First Posted Date
- 2017-03-01
- Last Posted Date
- 2024-03-29
- Lead Sponsor
- University of Texas Southwestern Medical Center
- Target Recruit Count
- 25
- Registration Number
- NCT03067467
- Locations
- 🇺🇸
UT Southwestern Medical Center, Dallas, Texas, United States
Cardiac (CMRI) Assessment of Acromegaly
- First Posted Date
- 2016-10-28
- Last Posted Date
- 2019-05-15
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 28
- Registration Number
- NCT02948322
- Locations
- 🇫🇷
AP-HP, Bicêtre Hospital, Le Kremlin Bicêtre, France
Ventilation and Pulmonary Endothelium Toxicities of E-cigarettes: A Randomized Crossover Pilot Study
- Conditions
- Interventions
- First Posted Date
- 2016-05-26
- Last Posted Date
- 2020-10-22
- Lead Sponsor
- Columbia University
- Target Recruit Count
- 12
- Registration Number
- NCT02783768
- Locations
- 🇺🇸
Columbia University Irving Medical Center, New York, New York, United States
Metabolic Imaging of the Heart Using Hyperpolarized (13C) Pyruvate Injection
- Conditions
- Interventions
- First Posted Date
- 2016-01-06
- Last Posted Date
- 2024-04-22
- Lead Sponsor
- Sunnybrook Health Sciences Centre
- Target Recruit Count
- 112
- Registration Number
- NCT02648009
- Locations
- 🇨🇦
Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
🇨🇦St. Michael's Hospital, Toronto, Ontario, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.